An observational study in Primary Biliary Cholangitis, sponsored by University of Milano Bicocca. Recruiting at 55 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-25.
Sponsored by University of Milano Bicocca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Liver Cirrhosis, Biliary with a site in Italy — 5 open to participants now, 11 under way, 4 of them phase 3. Liver Cirrhosis, Biliary · Italy.
Among the 25 studies in Liver Cirrhosis, Biliary with a site in Italy, this one is the only one that started in 2019, is one of 5 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 14th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →5 of the 25 studies in Liver Cirrhosis, Biliary with a site in Italy are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in Italy, Belgium, France and 2 more countries
Ages 18–70
Assistance Publique - Hôpitaux de Paris · Sites in Italy, Austria, Belgium and 4 more countries
Ages 18–70
Gilead Sciences · Sites in Italy, United States, Argentina and 26 more countries
Ages 18+
Ipsen · Sites in Italy, United States, Argentina and 25 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 10 · Phase 4 2
First in 2012; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,000 is above the median of 380 across 54 observational studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 207 across the 19 interventional studies, 630 across the 5 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 10 most frequent:
University of Milano Bicocca is the lead sponsor of 126 studies on the registry; 47 are open to participants now.
University of Milano Bicocca has 1 study filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
3 of the studies in Liver Cirrhosis, Biliary with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07573514Fondazione Policlinico Universitario Agostino Gemelli IRCCSPatients With Primary Biliary Cholangitis | 2026-12 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07629128Fondazione Policlinico Universitario Agostino Gemelli IRCCSPatients With Primary Biliary Cholangitis(PBC) | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Liver Cirrhosis, Biliary with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary biliary cholangitis (PBC) is a rare, autoimmune, cholestatic liver disease. No data about the disease epidemiology exist in Italy. Therefore this study aims to develop a national PBC patient database linked to a biological sample storage.
Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by chronic inflammation of the intrahepatic bile ducts, causing progressive ductopenia, cholestasis, and if not effectively treated, leading to fibrosis, cirrhosis and liver failure. Nowadays almost all patients with PBC are diagnosed at an early disease stage and receive treatment with ursodeoxycholic acid (UDCA) which is currently the only drug approved for the treatment of patients with PBC. However, approximately 20% to 30% (up to >50% in patients presenting under the age of 40 years) still does not have a benefit from UDCA and has a reduced prognosis as compared to healthy individuals. Major steps forwards in the field of PBC have been done in the last decade, however there are still significant areas of unmet clinical need in PBC: the lack of knowledge on etiopathogenesis; a poor understanding of disease sub-phenotypes; the lack of biomarkers of disease progression that allow risk stratification needed in clinical management and trials design, among the others. In the current evolving research landscape with the availability of the -omics technologies generating libraries of genome-wide data, metabolomics and proteomics data, among the others, the prospects of discovering the gene and molecular underpinnings of PBC are more promising than ever. Scientists envision an era of "personalized medicine" when more and more people will obtain their own genetic and metabolic maps, enabling them to identify their status as carriers of specific risk profiles.
Based on these premises, the current project aims to build up a research, nation-wide infrastructure (around 60 Italian participating centres will be involved) to study the biology of PBC and, in particular, to explore why a significant group of, typically young patients fail primary therapy with UDCA, placing them at risk of developing progressive disease and needing liver transplantation (LT). The investigators will recruit patients and organise the collection of important clinical information and laboratory investigation, together with biological samples. Data will be collected in the form of electronic Case Report Forms (REDCap cloud) that will be completed by clinicians at baseline and thereafter on an annual basis. The clinical information will allow us to identify patients' clinical profiles. The biological samples will allow to understand key aspects of people's make up, including patient genes and the way their immune system works, and the differences in make up between people with different clinical phenotypes.
This research infrastructure would represent an invaluable resource for successful translational research in this field. Specifically, it would serve investigators conducting research; clinicians treating patients; epidemiologists gathering demographic data; and the drug and device industry seeking new markets. It also can represent a necessary infrastructure for the implementation of the European Reference Networks (ERN) for rare diseases, main pillars of the current EU policy framework on National Plans for research and development. The Italian PBC database would also be crucial for drug development, specifically to assess the feasibility of clinical trials, to facilitate the planning of appropriate clinical trials, to support the enrolment of patients and to assess the impact of new interventions.
All the italian patients fulfilling the diagnostic criteria for Primary Biliary Cholangitis (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67) and aged at least 18.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All PBC patients living in Italy and aged at least 18 years can be included in the database. According to well-established criteria, PBC is diagnosed in subjects who fulfill two of the three of following criteria:
Exclusion Criteria:
The patient has explicitly declared his/her unwillingness to participate to the study
All PBC patients living in Italy and aged at least 18 years can be included in the database. According to well-established criteria, PBC is diagnosed in subjects who fulfill two of the three of following criteria: 1. elevated alkaline phosphatase and /or GGT; 2. positive anti-mitochondrial autoantibodies (titer ≥ 1:40) or PBC-specific antinuclear antibodies (gp-210 and sp100); 3. characteristic histological features of florid bile ducts lesions and granulomatous lesion.
Other: Clinical information
The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
Also known as: Laboratory information, Biological samples
Phenotypes and sub-phenotypes of PBC Italian patients
Identify and define distinct phenotypes and sub-phenotypes of PBC patients at higher risk of disease progression.
Time frame: Overall duration of the study (10 years)
Response to UDCA therapy
Defined as Alkaline Phosphatase Level\<1 x upper limit of normal. The investigators will fit a multivariate analysis using logistic regression using baseline variables.
Time frame: Overall duration of the study (10 years)
Identification of factors influencing the progression of PBC
The investigators will calculate the time from the diagnosis of PBC to an event (liver decompensation, liver transplantation or death). They will then fit a multivariate analysis using Cox's proportional hazards regression model of diverse explanatory variables available at baseline.
Time frame: Overall duration of the study (10 years)
Safety and long-term efficacy of novel therapies
The investigators will evaluate prospectively laboratory investigation and the treatment response to novel therapies that are entering the clinical practice, e.g. obeticholic acid, fibrates.
Time frame: Overall duration of the study (10 years)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2019 (actual). Primary completion is estimated for Jan 2029, 112 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Milano Bicocca →